Core Insights - HBC reported total operating revenues of NOK 60.9 million in Q1 2025, a 15% increase from NOK 52.4 million in Q1 2024, driven by growth in higher-margin human and pet health segments despite production constraints and commodity oil market pressures [1][6] - The company experienced a significant increase in B2B sales in the human segment, with a 66% year-over-year growth, particularly for products like OmeGo® and ProGo® [6] - HBC launched an unsecured bond that closed after the quarter with subscriptions of approximately CHF 3.5 million, indicating strong investor interest [6] Financial Performance - Cost of goods sold (CoGS) rose to NOK 37.5 million from NOK 27.3 million in Q1 2024, while operating expenses slightly decreased to NOK 23.1 million from NOK 23.9 million [2] - EBITDA for the quarter was negative NOK 19.9 million, compared to NOK -16.2 million in Q1 2024, with operational EBITDA at NOK -8.3 million [3] - The first quarter included NOK 3.0 million in one-time restructuring costs aimed at improving long-term operational efficiency [2][3] Product and Market Developments - HBC's product offerings include ProGo®, OmeGo®, and CalGo® / NT-II®, which are designed to enhance human and pet health [5] - The company achieved a record production period at its Midsund facility, operating 15-20% above its rated capacity while maintaining quality [6] - Clinical studies have shown that OmeGo® significantly reduces coughing and improves sleep in individuals exposed to pollution, while NT-II™ demonstrated improvements in joint pain and stiffness [6][7] Strategic Initiatives - HBC is expanding its production capacity at Berkåk to triple output, reflecting confidence in future demand [6] - The company has made significant advances in pharmaceutical research, including programs targeting prostate cancer and asthma, and has established a biotech-focused spin-off, HBC Immunology [7] - HBC participated in major industry events, reinforcing its leadership in marine-based nutrition and expanding its market presence [6]